1 / 30

Bio Balance Corporation

Bio Balance Corporation. Improving Medications Using Cost-Effective Processes. Building a Broad and Flexible Technology. Enhancing the safety and efficacy of existing pharmaceuticals & Creating new pharmaceuticals. G Protein-Coupled Receptors (GPCRs).

floyd
Download Presentation

Bio Balance Corporation

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Bio Balance Corporation Improving Medications Using Cost-Effective Processes

  2. Building a Broad and Flexible Technology Enhancing the safety and efficacy of existing pharmaceuticals & Creating new pharmaceuticals

  3. G Protein-Coupled Receptors(GPCRs) • It is conservatively estimated that 30-50% of all pharmaceuticals interact with GPCRs. • These receptors are widely distributed within our bodies and are integral to our senses, thoughts and sensations. • They all desensitize to continued stimulation by agonists.

  4. Gsa – Heart, brain,lung, neurons, kidney, liver, adrenal gland Gia – Brain, olfactory, heart, all tissues Activate Ca2+ channels, cardiac positive inotropy, contractile proteins Regulate K+, Ca2+ channels, inhibit cAMP and Ca/CaM actions Some Common GPCRs -Their Distribution and Effector Systems Distribution: Effects:

  5. The Problem of Desensitization

  6. Desensitization Fade Autoinhibition Tachyphylaxis Tolerance Down-regulation Resistance Terminology

  7. The History of Desensitization

  8. Interesting and Historical Points: 1957 – First detailed experimental observations of receptor desensitization by del Castillo & Katz Proc.Roy. Soc. Lond. 146, 369-381. 1972 – From search - one paper titled “receptor desensitization by lobeline and nicotine” 1988 – The Rose patent # 5,316,759 (May 31, 1994) refers to work dating back to 1988 on the agonist-antagonist combination of nicotine with mecamylamine. 1991 – Geoffroy, et al. “Reduction of Desensitization of a Glutamate Ionotropic Receptor by Antagonists” Molecular Pharmacology 39, 587-591.

  9. Patents Combining Agonists with Antagonists

  10. Scientific Objective:Preventing Desensitization

  11. Methodology Medication (“agonist” – e.g., isoproterenol, morphine) + Antagonist to prevent desensitization (“antagonist” – e.g., metoprolol, naloxone) = New & Improved Medication

  12. The Heart of Bio Balance’s Technology The determination of the optimal ratio of agonist and antagonist by our patented method. This method is based upon a biophysical model for the receptor response. This allows Bio Balance to create patentable compositions using the “best mode” of practice.

  13. A Representation of the two-state model showing 5-HT binding

  14. Experimental vs. Theoretical curves for various receptor responses

  15. Applications of Bio Balance’s Technology • Extend the patent protection of existing drugs • Create new drugs as combinations of generic drugs • Assist in drug development by salvaging previously discarded drug candidates because of excessive desensitization or fade

  16. Advantages of Bio Balance’s Technology • Better control of the therapeutic response. • Cheaper to develop • Multiple therapeutic areas can be targeted • Can combine generic drugs • Potentially quick acceptance by physicians as a technically superior design of previously accepted drugs. • Multiple new drugs can be created as compositions within several therapeutic areas such as cardiovascular, pain, pulmonary, brain/memory, tocolytic, etc.

  17. Bio Balance’sTherapeutic Targets Heart Asthma Pain Memory Other GPCRs Premature Labor

  18. Conclusion Bio Balance has a broad and flexible technology to enhance existing pharmaceuticals and to create new pharmaceuticals that work better with fewer side-effects.

More Related